NewsBenzingaCalidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings Calidi Biotherapeutics To Present Preclinical Data On CLD-401 And In Situ T-Cell Engager Programs At ESMO 2026, Highlighting Tumor Eradication And Antitumor Activity Findings Benzinga 2026.10.19 12:06 (GMT+0) Open on Benzinga Other news Interactive Brokers Increased Its Dividend by More Than 70%. What This Means for IBKR Stock. Here’s How Much You Would Have Made Owning Visa Stock In The Last 15 Years Here's How Much $1000 Invested In PBF Energy 5 Years Ago Would Be Worth Today Kevin O’Leary Says Tesla-SpaceX Merger Is Inevitable After Flying Roadster Demo — ‘If You Own Tesla, You’re Gonna Own New Company’ Blackstone’s Jas Khaira says fears over AI-buildout debt are overblown Cathay General Q3 2026 Earnings Call Transcript
Kevin O’Leary Says Tesla-SpaceX Merger Is Inevitable After Flying Roadster Demo — ‘If You Own Tesla, You’re Gonna Own New Company’
